Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through this collaboration, Servier has worked with Mission Bio’s Pharma Assay Development services to utilize Tapestri single-cell DNA sequencing technology to serially assess hundreds of samples with IDH1-mutated AML who have been treated with TIBSOVO (ivosidenib).
Lead Product(s): Ivosidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Tibsovo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Servier
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022